Citation: | WANG Ennan, CHEN Yi, CHU Shuzhen. Comparison of Sino-Japanese innovative drug market access policy environment and enlightenment to China[J]. Journal of China Pharmaceutical University, 2017, 48(6): 745-750. DOI: 10.11665/j.issn.1000-5048.20170618 |
[1] |
China Food and Drug Administration.Notice of the General Administration of the People′s Republic of China on the Release of the Work Plan for Registration of Chemical Registration[EB/OL].(2016-03-04)/[2016-12] .http://www.sda.gov.cn/WS01/CL0087/146140.html.
|
[2] |
Ding JX,Luo QW,Wang YW.Evaluation of Japanese drug data protection system and its enlightenment to China-An empirical study based on the performance of Japan′s innovative drugs reexamination policy[J].Shanghai Med Pharm J(上海医药),2011,32(12):615-620.
|
[3] |
Gao Y.Japan′s Drug Price Management system and its enlightenment[J].Macroeconomic Management(宏观经济管理),2015(10):84-85,92.
|
[4] |
Shi QB.The mechanism and effect of government drug price regulation:an empirical study of Japanese medicine pricing[J].Price:Theory & Practice(价格理论与实践),2009(4):75-76.
|
[5] |
Sun Y,Sun LH.Impact for new drug price management on pharmaceutical innovation[J].Chin J Pharm(中国医药工业杂志),2011,42(3):236-240.
|
[6] |
Yang JX,Wang XY.Japans medicare system and its implication to China[J].Northeast Asia Forum(东北亚论坛),2010,9(1):115-122.
|
[7] |
Luo SN, Ma AX. The management mode of drug purchasing in america and Japan and its enlightenment to China[J].Shanghai Med Pharm J(上海医药),2008,29(6):258-260.
|